share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP：信函
美股sec公告 ·  04/13 01:23
牛牛AI助理已提取核心訊息
Apollomics Inc., a biopharmaceutical company, has responded to a comment from the SEC regarding its operations in China. The SEC's Division of Corporation Finance had requested clarification on the extent of Apollomics' operations in China, citing the need for specific disclosures about the risks associated with China-based companies. In a letter dated April 12, 2024, Apollomics clarified that it does not conduct the majority of its operations in China, stating that it is a Cayman Islands holding company with its business headquarters and management team based in California, USA. The company conducts most of its research and development efforts outside of China, with less than 20% of these activities taking place in Hong Kong and mainland China through its subsidiaries. Apollomics also highlighted that the majority of its cash and expenditures are held and incurred outside of China. This response follows the SEC's guidance on China-specific disclosures and addresses issues previously raised in a December 2021 letter.
Apollomics Inc., a biopharmaceutical company, has responded to a comment from the SEC regarding its operations in China. The SEC's Division of Corporation Finance had requested clarification on the extent of Apollomics' operations in China, citing the need for specific disclosures about the risks associated with China-based companies. In a letter dated April 12, 2024, Apollomics clarified that it does not conduct the majority of its operations in China, stating that it is a Cayman Islands holding company with its business headquarters and management team based in California, USA. The company conducts most of its research and development efforts outside of China, with less than 20% of these activities taking place in Hong Kong and mainland China through its subsidiaries. Apollomics also highlighted that the majority of its cash and expenditures are held and incurred outside of China. This response follows the SEC's guidance on China-specific disclosures and addresses issues previously raised in a December 2021 letter.
生物製藥公司Apollomics Inc. 對美國證券交易委員會關於其在中國業務的評論做出了回應。美國證券交易委員會公司財務部要求澄清Apollomics在中國的業務範圍，理由是需要具體披露與中國公司相關的風險。在2024年4月12日的一封信中，Apollomics澄清說，其大部分業務並不在中國進行，稱其是一家開曼群島控股公司，其業務總部和管理團隊位於美國加利福尼亞州。該公司的大部分研發工作都在中國境外進行，其中只有不到20％的活動是通過其子公司在香港和中國大陸進行的。Apollomics還強調，其大部分現金和支出都是在中國境外持有和發生的。該回應遵循美國證券交易委員會關於中國特定披露的指導方針，並解決了先前在2021年12月的信函中提出的問題。
生物製藥公司Apollomics Inc. 對美國證券交易委員會關於其在中國業務的評論做出了回應。美國證券交易委員會公司財務部要求澄清Apollomics在中國的業務範圍，理由是需要具體披露與中國公司相關的風險。在2024年4月12日的一封信中，Apollomics澄清說，其大部分業務並不在中國進行，稱其是一家開曼群島控股公司，其業務總部和管理團隊位於美國加利福尼亞州。該公司的大部分研發工作都在中國境外進行，其中只有不到20％的活動是通過其子公司在香港和中國大陸進行的。Apollomics還強調，其大部分現金和支出都是在中國境外持有和發生的。該回應遵循美國證券交易委員會關於中國特定披露的指導方針，並解決了先前在2021年12月的信函中提出的問題。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。